American Century Companies Inc. Acquires 430 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

American Century Companies Inc. grew its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 0.2% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 231,254 shares of the company’s stock after purchasing an additional 430 shares during the quarter. American Century Companies Inc. owned about 0.21% of Apellis Pharmaceuticals worth $15,226,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in APLS. Clearstead Advisors LLC acquired a new position in Apellis Pharmaceuticals during the 1st quarter worth about $27,000. Parallel Advisors LLC increased its holdings in shares of Apellis Pharmaceuticals by 1,173.0% in the first quarter. Parallel Advisors LLC now owns 942 shares of the company’s stock valued at $62,000 after purchasing an additional 868 shares in the last quarter. US Bancorp DE increased its holdings in shares of Apellis Pharmaceuticals by 391.2% in the first quarter. US Bancorp DE now owns 1,110 shares of the company’s stock valued at $56,000 after purchasing an additional 884 shares in the last quarter. IFP Advisors Inc raised its position in Apellis Pharmaceuticals by 49,525.0% in the 1st quarter. IFP Advisors Inc now owns 1,985 shares of the company’s stock worth $39,000 after purchasing an additional 1,981 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Apellis Pharmaceuticals by 110.7% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 2,366 shares of the company’s stock worth $156,000 after buying an additional 1,243 shares in the last quarter. Institutional investors own 90.43% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on APLS. Stifel Nicolaus boosted their target price on Apellis Pharmaceuticals from $60.00 to $65.00 and gave the stock a “buy” rating in a research report on Tuesday. Robert W. Baird cut their target price on shares of Apellis Pharmaceuticals from $115.00 to $70.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 1st. HC Wainwright reissued a “buy” rating and set a $82.00 price target on shares of Apellis Pharmaceuticals in a research note on Wednesday, August 23rd. Wedbush reaffirmed a “neutral” rating and issued a $29.00 price objective on shares of Apellis Pharmaceuticals in a research note on Wednesday, August 23rd. Finally, UBS Group upped their target price on shares of Apellis Pharmaceuticals from $60.00 to $64.00 and gave the company a “buy” rating in a research report on Wednesday, August 23rd. Six research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $65.20.

Apellis Pharmaceuticals Stock Performance

Shares of APLS stock opened at $43.48 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 4.52 and a current ratio of 5.11. Apellis Pharmaceuticals, Inc. has a 52 week low of $19.83 and a 52 week high of $94.75. The company’s 50 day moving average price is $49.56 and its two-hundred day moving average price is $67.85. The company has a market capitalization of $5.12 billion, a P/E ratio of -7.46 and a beta of 1.17.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Monday, July 31st. The company reported ($1.02) EPS for the quarter, beating the consensus estimate of ($1.35) by $0.33. Apellis Pharmaceuticals had a negative net margin of 356.02% and a negative return on equity of 212.82%. The business had revenue of $95.00 million for the quarter, compared to analysts’ expectations of $70.38 million. During the same period in the previous year, the firm posted ($1.46) EPS. The firm’s revenue was up 482.8% compared to the same quarter last year. On average, analysts expect that Apellis Pharmaceuticals, Inc. will post -4.96 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Apellis Pharmaceuticals news, insider Pascal Deschatelets sold 12,000 shares of the business’s stock in a transaction that occurred on Thursday, June 8th. The stock was sold at an average price of $91.35, for a total value of $1,096,200.00. Following the sale, the insider now owns 1,040,313 shares in the company, valued at approximately $95,032,592.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CFO Timothy Eugene Sullivan sold 69,779 shares of the company’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $88.80, for a total transaction of $6,196,375.20. Following the sale, the chief financial officer now owns 77,713 shares in the company, valued at $6,900,914.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Pascal Deschatelets sold 12,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 8th. The shares were sold at an average price of $91.35, for a total value of $1,096,200.00. Following the completion of the transaction, the insider now owns 1,040,313 shares of the company’s stock, valued at $95,032,592.55. The disclosure for this sale can be found here. Over the last three months, insiders sold 274,119 shares of company stock worth $16,443,449. 7.50% of the stock is owned by corporate insiders.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA).